A Study of SIGX1094R in Patients with Advanced Solid Tumors

Phase 1

Recruiting

• Conditions: Advanced Solid Tumors
• Interventions: Drug: SIGX1094R

• Registration Number: NCT06739291
• Lead Sponsor: Signet Therapeutics

Brief Summary

This is a phase I clinical, first-in-human study of SIGX1094R monotherapy. The goal of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), anti-tumor activity and food effect of SIGX1094R in patients with advanced solid tumors.

Detailed Description

The study consists of two parts: SIGX1094R dose escalation study; food effect and SIGX1094R multiple-dose expansion study.

Part of SIGX1094R dose escalation study:

* the primary objective is to evaluate the safety and tolerability of SIGX1094R, and to define the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D).

* the secondary objective is to evaluate the PK profile and preliminary efficacy of SIGX1094R, and to explore the relationship between PD parameters and efficacy.

Part of food effect and SIGX1094R multiple-dose expansion study:

* the primary objective is to evaluate the food effect on PK profile of SIGX1094R.

* the secondary objective is to further evaluate the anti-tumor activity, safety and tolerability of SIGX1094R, and to further evaluate the relationship between PD parameters and efficacy.

Study Timeline

• Status Verified: 2024-12
• Study First Submitted: 2024-12-06
• Study Start: 2024-12-12
• Study First Submitted QC: 2024-12-12
• Study First Posted: 2024-12-18
• Last Update Submitted: 2025-01-16
• Last Update Posted: 2025-01-20
• Primary Completion: 2026-02
• Study Completion: 2026-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

Patients must meet all of the following criteria before being enrolled in the study.

1. Subjects who are able to understand the procedures and methods of this clinical study, voluntarily participate in the study and sign the ICF.

2. Subjects aged ≥18 years when signing the ICF, male or female.

3. Patients with histologically, cytologically, or clinically proven advanced solid tumors (locally advanced or metastatic) that do not have standard treatment available, have disease progression on/after standard treatment, or cannot tolerate standard treatment.

4. Subjects with at least one evaluable tumor lesion according to the RECIST v1.1; subjects who have no measurable lesions but have assessable lesions are allowed to be enrolled as judged by the investigator.

5. Patients (according to subjects' wishes) will provide a pre-treatment tumor specimen (archival or fresh biopsy samples). If a fresh biopsy is required, procedures more invasive than a core biopsy or significant risk procedures for which the procedure-associated absolute risk of mortality or major morbidity in the patient's clinical setting and specific institution is 2% or higher, should not be utilized.

6. ECOG score ≤ 1 (patients with an ECOG score of 2 are allowed to be enrolled, as judged by the investigator).

7. Life expectancy ≥ 3 months

8. Subjects with good organ function, including:

   • Liver function (no history of liver protection therapy 7 days before screening): TBIL ≤ 1.5×ULN, ALT ≤ 3×ULN, AST ≤ 3×ULN (no liver metastasis); if there is liver metastasis, ALT and AST ≤ 5×ULN; albumin ≥ 30 g/L.
   • Renal function: Creatinine clearance ≥ 60 mL/min (calculated according to Cockcroft-Gault formula).
   • Hematology (no blood transfusion or hematopoietic stimulating factor treatment within 14 days; no treatment with erythropoietin or thrombopoietin within 7 days): ANC ≥ 1.5×10^9/L, PLT ≥ 100×10^9/L, and Hb ≥ 90 g/L.
   • Coagulation function: activated partial thromboplastin time ≤ 1.5 × ULN and international normalized ratio ≤ 1.5 × ULN.

9. Women of reproductive age must have a negative blood pregnancy test result within 7 days prior to the first dose and promise to adhere to fully effective contraception or abstinence from the beginning of the screening period until 6 months after the last dose of study treatment; male patients must promise to adhere to fully effective contraception or abstinence from the beginning of the screening period until 6 months after the last dose of study treatment.

Exclusion Criteria

Patients who meet any of the following criteria cannot be enrolled in this study.

1. Patients with hypersensitivity to the active ingredient or excipient ingredient of SIGX1094R, or a history of severe allergy.

2. Patients who have received cytotoxic chemotherapeutic drugs or small molecule targeted drugs within 4 weeks prior to the first dose. Note: For mitomycin C or nitrosoureas, 6-week washout is required; for small-molecule targeted drugs and oral fluorouracil drugs, a washout period of 2 weeks or 5 T1/2 of the drug (whichever is longer) is required.

3. Anti-tumor endocrine therapy, radiotherapy, interventional embolization, radiofrequency, proton therapy, radioimmunotherapy, immunotherapy or other biotherapies within 4 weeks prior to the first dose (if 5 T1/2 of the drug/therapy used by the patient is confirmed to be < 4 weeks, 5 T1/2 shall prevail).

4. Patients who have received anti-tumor treatment with medicine/proprietary medicine within 2 weeks prior to the first dose.

5. Patients who have received other clinical investigational drugs or therapies that are not on the market within 4 weeks or 5 T1/2 prior to the first dose.

6. Prior treatment with focal adhesion kinase (FAK) inhibitors.

7. Patients who have received moderate or strong cytochrome P450(CYP)3A4, CYP3A5, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 inhibitors, or moderate or strong CYP3A4 or CYP3A5 inducers, or moderate-to-strong P-gp and BCRP inhibitors, or moderate-to-strong Multidrug and toxin extrusion protein (MATE)1, MATE2-K, Organic anion transporter (OAT) 1, OAT3, Organic anion transporting polypeptide (OATP) 1B1, OATP1B3, Organic cation transporter (OCT) 2, Bile salt export pump (BSEP) inhibitors within 14 days prior to the first dose and cannot be discontinued for the duration of the study. Note: please see the https://www.fda.gov/drugs/drug- interactions labeling/drug-development-and-drug-interactions-table- substrates inhibitors-and-inducers for the Inhibitors and Inducers of the CYP enzyme or transporters.

8. Patients who have received an anti-acid drug or gastric acid reducing agents within 14 days prior to the first dose and cannot be discontinued for the duration of the study.

9. Pregnant or lactating women.

10. Patients whose adverse reactions of prior anti-tumor therapy assessed according to CTCAE V5.0 at the time of screening have not returned to Grade ≤ 1 (except for toxicities that are of no safety risk as judged by the investigator, such as alopecia, gasping, γ-glutamyl transferase (GGT) increased, ALP increased, grade 2 peripheral neurotoxicity, and decreased thyroid function stabilized by hormone replacement therapy).

11. Presence of clinically symptomatic metastases to central nervous system or meninges or other evidence showing that metastatic lesions in central nervous system or meninges have not yet been controlled at screening, which, at the investigator's discretion, is not suitable for enrollment. Note: Patients with central nervous system or meningeal metastases who are asymptomatic or stable after treatment prior to the first dose may be considered for enrollment.

12. A history of severe neurological or psychiatric disorders, including epilepsy, dementia, and moderate to severe depression.

13. History of drug abuse or dependence.

14. Clinically serious and uncontrolled cardiovascular diseases, including:

    • Serious arrhythmia or conduction abnormality at screening, such as ventricular arrhythmia that requires clinical intervention, atrioventricular block II-III degree, etc.
    • Myocardial infarction within 12 months prior to the first dose.
    • Acute coronary syndrome, cardiac failure congestive, aortic dissection, cerebral stroke or other grade ≥ 3 cardiovascular and cerebrovascular events within 6 months prior to the first dose.
    • Patients who have had arterial or deep vein thrombosis within 6 months prior to the first dose, or patients requiring INR monitoring or using anticoagulants at the time of screening; patients with hemorrhagic diseases, active ulcer, and experienced gastrointestinal perforation. Note: Patients with superficial venous thrombosis who do not require treatment may be considered for enrollment; patients who are able to stop anticoagulants within 2 weeks prior to the first dose and during medication may be considered for enrollment.
    • Patients with average QTcF of three 12-lead ECGs at screening > 470ms [Note: QTcF is calculated according to Fridericia formula, QTcF= QT/(RR^0.33)].
    • Patients with any risk factors that may prolong the QTc interval, such as uncorrectable hypokalemia, hereditary long QT syndrome, and the use of medications that prolong the QTc interval (primarily Class Ia, Ic, and III antiarrhythmic drugs).
    • Patients with New York Heart Association (NYHA) Class ≥ II cardiac failure at screening.
    • Left ventricular ejection fraction (LVEF) < 50% at screening.
    • Hypertension (defined as systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg) which has not been consistently controlled with medication at screening.

15. Patients with hyperglycemia that cannot be stably controlled with medication at screening.

16. Patients with pulmonary embolism within 6 months prior to the first dose, or interstitial pneumonia at screening.

17. Prior allogeneic stem cell transplantation, bone marrow transplantation or vital organ transplantation.

18. Patients who have undergone surgery on vital organs (other than aspiration biopsy) or suffered major trauma within 4 weeks prior to the first dose, or patients who have not recovered from any surgical effect at screening, or who are scheduled for major surgery during the study period.

19. Patients with uncontrolled infectious diseases, congenital immunodeficiency diseases, acquired immunodeficiency syndrome [human immunodeficiency virus antibody (HIV-Ab) positive], syphilis (syphilis antibody-positive), or active hepatitis B [hepatitis B virus (HBV) - deoxyribonucleic acid (DNA) >500 IU/ml]; hepatitis C virus (HCV) infection (HCV antibody positive and HCV ribonucleic acid amplification quantitative test positive). Patients with well controlled HIV, HBV, and HCV infections may be enrolled with no significant safety risk in the judgment of the investigator; see https://www.fda.gov/media/121319/download for definition of well controlled.

20. Patients with severe active infection, including but not limited to bacteremia and severe pneumonia within 2 weeks prior to the first dose; patients with an active infection requiring intravenous antibiotics within 2 weeks prior to the first dose.

21. Patients with conditions that may affect drug absorption as judged by the investigator, such as dysphagia, chronic diarrhea, or prior small bowel resection.

22. Patients with active autoimmune diseases, such as rheumatic disorder and rheumatoid disease.

23. The investigator considers that the patient is not suitable for participating in this study (e.g., study drug is not in the best interest of patient, patients with mental disorder, patients with poor compliance, etc.).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
SIGX1094R	SIGX1094R	Oral SIGX1094R administered once daily.

Primary Outcome Measures

Name	Time	Method
Incidence of adverse events (AEs)	From the first dose to 28 days after the last dose. Last for approximately 18 months.	To evaluate the safety and tolerability of SIGX1094R. AEs will be evaluated per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE),Version 5.0.
Incidence of serious adverse events (SAEs)	From the first dose to 28 days after the last dose. Last for approximately 18 months.	To evaluate the safety and tolerability of SIGX1094R. SAEs will be evaluated per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE),Version 5.0.
Abnormalities or changes in laboratory tests	Approximately 18 months	To evaluate the safety and tolerability of SIGX1094R.
Abnormalities or changes in vital signs	Approximately 18 months	To evaluate the safety and tolerability of SIGX1094R.
Abnormalities or changes in electrocardiograms (ECGs)	Approximately 18 months	To evaluate the safety and tolerability of SIGX1094R.
Abnormalities or changes in physical examinations	Approximately 18 months	To evaluate the safety and tolerability of SIGX1094R.
Abnormalities or changes in Eastern Oncology Collaborative Group (ECOG) scores	Approximately 18 months	To evaluate the safety and tolerability of SIGX1094R.
Incidence of dose-limiting toxicity (DLT) events	From the first treatment of single dosing (5 days in single dosing period ) to the end of Cycle 1 (21 days a Cycle in multiple dosing period ).	Collect the incidence, classification, severity, and frequency of DLT. To evaluate the safety and tolerability of SIGX1094R.
Maximum tolerated dose (MTD)	Approximately 18 months	To determine the MTD of SIGX1094R.
Recommended phase 2 dose (RP2D)	Approximately 18 months	To determine the RP2D of SIGX1094R.

Secondary Outcome Measures

Name	Time	Method
Clinical benefit rate (CBR)	Approximately 18 months	Proportion of subjects whose best response is observed to be CR, PR, or SD (duration ≥ 24 weeks) throughout the study.
Maximum observed concentration (Cmax)	Time points at Day 1 to Day 5 in single-dose period. Time points at Cycle 1 Day1, Cycle 1 Day 8, Cycle 1 Day15, Cycle 1 Day 21 in Cycle 1, and Cycle n Day 1 from Cycle 2, in multiple-dose period. Each Cycle is 21 days.	To assess pharmacokinetics (PK) of SIGX1094R in plasma following a single and multiple doses of SIGX1094R.
Time of maximum observed concentration (Tmax)	Time points at Day 1 to Day 5 in single-dose period. Time points at Cycle 1 Day1, Cycle 1 Day 8, Cycle 1 Day15, Cycle 1 Day 21 in Cycle 1, and Cycle n Day 1 from Cycle 2, in multiple-dose period. Each Cycle is 21 days.	To assess PK of SIGX1094R in plasma following a single and multiple doses of SIGX1094R.
Area under the concentration-time curve (AUC)	Time points at Day 1 to Day 5 in single-dose period. Time points at Cycle 1 Day1, Cycle 1 Day 8, Cycle 1 Day15, Cycle 1 Day 21 in Cycle 1, and Cycle n Day 1 from Cycle 2, in multiple-dose period. Each Cycle is 21 days.	To assess PK of SIGX1094R in plasma following a single and multiple doses of SIGX1094R.
Half-life (t1/2)	Time points at Day 1 to Day 5 in single-dose period. Time points at Cycle 1 Day1, Cycle 1 Day 8, Cycle 1 Day15, Cycle 1 Day 21 in Cycle 1, and Cycle n Day 1 from Cycle 2, in multiple-dose period. Each Cycle is 21 days.	To assess PK of SIGX1094R in plasma following a single and multiple doses of SIGX1094R.
Objective response rate (ORR)	Approximately 18 months	Proportion of subjects whose best response is observed to be complete response (CR) or partial response (PR) throughout the study. Assessed by RECIST 1.1 criteria.
Progression-free survival (PFS)	Approximately 18 months	Time from Day 1 of treatment with the study drug to progressive disease (PD) or death from any cause. Assessed by RECIST 1.1 criteria.
Duration of response (DOR)	Approximately 18 months	Time from first tumor assessment of CR or PR on study treatment to first assessment of PD or death due to any cause. Assessed by RECIST 1.1 criteria.
Overall survival (OS)	Approximately 18 months	Time from Day 1 of treatment with the study drug to death from any cause. Assessed by RECIST 1.1 criteria.
Disease control rate (DCR)	Approximately 18 months	Proportion of subjects whose best response is observed to be CR, PR, or stable disease (SD) (duration ≥ 12 weeks) throughout the study. Assessed by RECIST 1.1 criteria.
Changes of phosphorylated Focal Adhesion Kinase (pFAK) in tumor tissues	Baseline to approximately 18 months	Determine the changes of phosphorylated Focal Adhesion Kinase (pFAK) from baseline in tumor tissues and assess its relationship with efficacy.

Trial Locations

Locations (1)

Beijing Cancer Hospital; 🇨🇳 Beijing, China